Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study -

NCT01862965 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT01862965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01862965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study -
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 2
Overall status
Completed
Start date
March 6, 2013
Completion date
March 31, 2019
Enrollment
38 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host disease